Literature DB >> 33397636

Langerhans cell histiocytosis in a 5-month-old baby.

Neil Chanchlani1, Simon C Parke2, James W Hart2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33397636      PMCID: PMC7774477          DOI: 10.1503/cmaj.201151

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
A 2-month-old boy presented to his family physician with areas of petechiae, confluent erythema, crusted pustules and hyperemia in the skin creases behind his ears, and in the neck, axilla and groin creases. The family physician diagnosed infected eczema and treated him with topical beta-methasone dipropionate and oral amoxicillin, but the rash did not improve. At 5 months of age, while growing well along centiles, the patient presented to hospital with worsening skin changes (Figure 1) and a 2-day history of fever, bilious vomiting, diarrhea and edema. Blood test results were as follows: hemoglobin, 84 (normal 95–135) g/L; mean corpuscular volume, 86 (normal 74–108) fL; white blood cell count, 11.4 (normal 6.0–17.5) × 109/L; platelet count, 107 (normal 150–400) × 109/L; bilirubin, 9 (normal < 21) μmol/L; and albumin, 17 (normal 30–45) g/L. Renal and liver function tests were normal. A lytic lesion on the patient’s left proximal femur was found on a skeletal survey.
Figure 1:

Photographs of a 5-month-old boy showing petechiae, confluent erythema, crusted papules and hyperemia in the skin creases involving the ears (A), neck (B), axilla (C) and groin (D). Vesicles and ulcers in the ear and groin creases, and areas of maceration in the neck, axilla and groin are seen.

Photographs of a 5-month-old boy showing petechiae, confluent erythema, crusted papules and hyperemia in the skin creases involving the ears (A), neck (B), axilla (C) and groin (D). Vesicles and ulcers in the ear and groin creases, and areas of maceration in the neck, axilla and groin are seen. Skin and duodenal biopsies were positive for Langerhans cell histiocytosis, and we identified involvement in multiple sites (dermatological, hematological, bone and gastrointestinal). The patient responded poorly to vinblastine and prednisolone; as he tested positive for the BRAF V600E mutation, he was started on dabrafenib, a BRAF kinase inhibitor, with clinical improvement. Langerhans cell histiocytosis is a proliferative disorder with an incidence of 5.8 cases per million among children.1 It is characterized by an accumulation of antigen-presenting dendritic (Langerhans) cells.1 A rash, often misdiagnosed as eczema, allergy or scabies, is a common presenting feature.2 Patients may also present with isolated, painful lytic bone lesions, typically in the skull; polyuria and polydipsia secondary to diabetes insipidus; chronic otitis media; or features of multisite disease, including bone marrow suppression (cytopenia), lymphadenopathy and hepatosplenomegaly. 3 Complications and death occur in up to 50% of cases.4 Red flags for considering diagnoses other than eczema include a lack of response to topical steroids, fever of unknown origin, generalized petechiae unrelated to excoriation, an atypical pattern (e.g., involvement of axilla and groin) or persistent irritability.3
  4 in total

1.  Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age.

Authors:  Charlotte Rigaud; Mohamed A Barkaoui; Caroline Thomas; Yves Bertrand; Anne Lambilliotte; Jean Miron; Nathalie Aladjidi; Geneviève Plat; Eric Jeziorski; Claire Galambrun; Ludovic Mansuy; Patrick Lutz; Anne Deville; Corinne Armari-Alla; Yves Reguerre; Sylvie Fraitag; Aurore Coulomb; Virginie Gandemer; Nicolas Leboulanger; Despina Moshous; Khe Hoang-Xuan; Abdellatif Tazi; Sébastien Heritier; Jean-François Emile; Jean Donadieu
Journal:  Br J Haematol       Date:  2016-06-07       Impact factor: 6.998

Review 2.  Langerhans-Cell Histiocytosis.

Authors:  Carl E Allen; Miriam Merad; Kenneth L McClain
Journal:  N Engl J Med       Date:  2018-08-30       Impact factor: 91.245

Review 3.  Langerhans cell histiocytosis in children: Diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up.

Authors:  Jolie Krooks; Milen Minkov; Angela G Weatherall
Journal:  J Am Acad Dermatol       Date:  2018-06       Impact factor: 11.527

4.  Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.

Authors:  Riccardo Haupt; Milen Minkov; Itziar Astigarraga; Eva Schäfer; Vasanta Nanduri; Rima Jubran; R Maarten Egeler; Gritta Janka; Dragan Micic; Carlos Rodriguez-Galindo; Stefaan Van Gool; Johannes Visser; Sheila Weitzman; Jean Donadieu
Journal:  Pediatr Blood Cancer       Date:  2012-10-25       Impact factor: 3.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.